Titre : Récepteurs CCR5

Récepteurs CCR5 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Case-Control Studies
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Récepteurs CCR5 : Questions médicales les plus fréquentes", "headline": "Récepteurs CCR5 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Récepteurs CCR5 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-05", "dateModified": "2025-03-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Récepteurs CCR5" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Récepteur VIH", "url": "https://questionsmedicales.fr/mesh/D015728", "about": { "@type": "MedicalCondition", "name": "Récepteur VIH", "code": { "@type": "MedicalCode", "code": "D015728", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.830.700" } } }, "about": { "@type": "MedicalCondition", "name": "Récepteurs CCR5", "alternateName": "Receptors, CCR5", "code": { "@type": "MedicalCode", "code": "D019713", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Richard G Pestell", "url": "https://questionsmedicales.fr/author/Richard%20G%20Pestell", "affiliation": { "@type": "Organization", "name": "Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, PA, United States; Wistar Institute, Philadelphia, PA, United States; Xavier University School of Medicine, Woodbury, NY, United States. Electronic address: richard.pestell@bblumberg.org." } }, { "@type": "Person", "name": "Xuanmao Jiao", "url": "https://questionsmedicales.fr/author/Xuanmao%20Jiao", "affiliation": { "@type": "Organization", "name": "Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, PA, United States." } }, { "@type": "Person", "name": "Yang Shen", "url": "https://questionsmedicales.fr/author/Yang%20Shen", "affiliation": { "@type": "Organization", "name": "Neurobiology, Psychiatry and Psychology Departments & Integrative Center for Learning and Memory, UCLA, Los Angeles, CA." } }, { "@type": "Person", "name": "Miou Zhou", "url": "https://questionsmedicales.fr/author/Miou%20Zhou", "affiliation": { "@type": "Organization", "name": "College of Dental Medicine, Western University of Health Sciences, Pomona, CA. Electronic address: mzhou@westernu.edu." } }, { "@type": "Person", "name": "Raquel Blanco", "url": "https://questionsmedicales.fr/author/Raquel%20Blanco", "affiliation": { "@type": "Organization", "name": "Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB/CSIC), Madrid, Spain." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A case-control study on immunologic markers of patients with vitiligo.", "datePublished": "2022-10-14", "url": "https://questionsmedicales.fr/article/36244264", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biopha.2022.113785" } }, { "@type": "ScholarlyArticle", "name": "Case-Control Study of Long COVID, Sapporo, Japan.", "datePublished": "2023-04-12", "url": "https://questionsmedicales.fr/article/37044126", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3201/eid2905.221349" } }, { "@type": "ScholarlyArticle", "name": "Endothelium-biomarkers for postthrombotic syndrome: a case-control study.", "datePublished": "2023-03-29", "url": "https://questionsmedicales.fr/article/37016998", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MBC.0000000000001192" } }, { "@type": "ScholarlyArticle", "name": "Risk Factors for Postoperative Pneumonia: A Case-Control Study.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35875004", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2022.913897" } }, { "@type": "ScholarlyArticle", "name": "Significance of temperature in antimuscarinic toxicity: a case-control study.", "datePublished": "2022-06-23", "url": "https://questionsmedicales.fr/article/35735006", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/15563650.2022.2088378" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Récepteurs de surface cellulaire", "item": "https://questionsmedicales.fr/mesh/D011956" }, { "@type": "ListItem", "position": 6, "name": "Récepteurs viraux", "item": "https://questionsmedicales.fr/mesh/D011991" }, { "@type": "ListItem", "position": 7, "name": "Récepteur VIH", "item": "https://questionsmedicales.fr/mesh/D015728" }, { "@type": "ListItem", "position": 8, "name": "Récepteurs CCR5", "item": "https://questionsmedicales.fr/mesh/D019713" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Récepteurs CCR5 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Récepteurs CCR5", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Récepteurs CCR5", "description": "Comment diagnostiquer une infection par le VIH ?\nQuels tests évaluent les récepteurs CCR5 ?\nQuels symptômes indiquent une infection par le VIH ?\nComment évaluer la résistance au VIH ?\nQuel rôle joue CCR5 dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D019713?mesh_terms=Case-Control+Studies&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Récepteurs CCR5", "description": "Quels sont les symptômes d'une infection par le VIH ?\nComment les récepteurs CCR5 affectent-ils l'immunité ?\nQuels symptômes sont liés à l'inhibition de CCR5 ?\nLes symptômes varient-ils selon le génotype de CCR5 ?\nQuels signes indiquent une progression de l'infection ?", "url": "https://questionsmedicales.fr/mesh/D019713?mesh_terms=Case-Control+Studies&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Récepteurs CCR5", "description": "Comment prévenir l'infection par le VIH ?\nQuel rôle joue l'éducation dans la prévention ?\nLes vaccins contre le VIH existent-ils ?\nComment la PrEP aide-t-elle à prévenir le VIH ?\nLes tests réguliers sont-ils importants ?", "url": "https://questionsmedicales.fr/mesh/D019713?mesh_terms=Case-Control+Studies&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Récepteurs CCR5", "description": "Quels traitements ciblent les récepteurs CCR5 ?\nComment les traitements antirétroviraux agissent-ils ?\nQuels sont les effets secondaires des inhibiteurs de CCR5 ?\nLes traitements sont-ils efficaces pour tous les patients ?\nComment surveiller l'efficacité du traitement ?", "url": "https://questionsmedicales.fr/mesh/D019713?mesh_terms=Case-Control+Studies&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Récepteurs CCR5", "description": "Quelles complications peuvent survenir avec le VIH ?\nComment les récepteurs CCR5 influencent-ils les complications ?\nQuels sont les risques de résistance aux traitements ?\nLes complications sont-elles réversibles ?\nComment prévenir les complications liées au VIH ?", "url": "https://questionsmedicales.fr/mesh/D019713?mesh_terms=Case-Control+Studies&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Récepteurs CCR5", "description": "Quels sont les principaux facteurs de risque du VIH ?\nLe génotype de CCR5 influence-t-il le risque d'infection ?\nComment l'usage de drogues affecte-t-il le risque ?\nLes antécédents familiaux influencent-ils le risque ?\nQuel rôle joue l'âge dans le risque d'infection ?", "url": "https://questionsmedicales.fr/mesh/D019713?mesh_terms=Case-Control+Studies&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection par le VIH ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un test sanguin détectant les anticorps ou l'ARN du VIH est utilisé." } }, { "@type": "Question", "name": "Quels tests évaluent les récepteurs CCR5 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de surface cellulaire peuvent être effectués." } }, { "@type": "Question", "name": "Quels symptômes indiquent une infection par le VIH ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Symptômes incluent fièvre, fatigue, éruptions cutanées et ganglions enflés." } }, { "@type": "Question", "name": "Comment évaluer la résistance au VIH ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de résistance virale mesurent l'efficacité des traitements antirétroviraux." } }, { "@type": "Question", "name": "Quel rôle joue CCR5 dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "CCR5 est un co-récepteur essentiel pour l'entrée du VIH dans les cellules." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une infection par le VIH ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, fatigue, maux de tête et éruptions cutanées." } }, { "@type": "Question", "name": "Comment les récepteurs CCR5 affectent-ils l'immunité ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Ils modulent la réponse immunitaire, influençant l'inflammation et l'infection." } }, { "@type": "Question", "name": "Quels symptômes sont liés à l'inhibition de CCR5 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Une inhibition peut réduire l'inflammation, mais causer des effets secondaires." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le génotype de CCR5 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines variations génétiques peuvent influencer la gravité des symptômes." } }, { "@type": "Question", "name": "Quels signes indiquent une progression de l'infection ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Perte de poids, infections opportunistes et fatigue chronique sont des signes." } }, { "@type": "Question", "name": "Comment prévenir l'infection par le VIH ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des préservatifs, se faire dépister et prendre des médicaments préventifs." } }, { "@type": "Question", "name": "Quel rôle joue l'éducation dans la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation sur le VIH et les comportements à risque est cruciale pour la prévention." } }, { "@type": "Question", "name": "Les vaccins contre le VIH existent-ils ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, aucun vaccin efficace n'est disponible, mais des recherches sont en cours." } }, { "@type": "Question", "name": "Comment la PrEP aide-t-elle à prévenir le VIH ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "La PrEP réduit le risque d'infection en bloquant l'entrée du VIH dans les cellules." } }, { "@type": "Question", "name": "Les tests réguliers sont-ils importants ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage régulier aide à détecter l'infection précocement et à prévenir sa propagation." } }, { "@type": "Question", "name": "Quels traitements ciblent les récepteurs CCR5 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les inhibiteurs de CCR5, comme le maraviroc, sont utilisés dans le VIH." } }, { "@type": "Question", "name": "Comment les traitements antirétroviraux agissent-ils ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils bloquent la réplication virale, empêchant le VIH d'infecter de nouvelles cellules." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des inhibiteurs de CCR5 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent causer des nausées, des éruptions cutanées et des infections respiratoires." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces pour tous les patients ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'efficacité dépend du génotype du VIH et de la réponse individuelle." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité du traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des tests réguliers de charge virale et de CD4 sont nécessaires pour évaluer la réponse." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le VIH ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent les infections opportunistes et les cancers associés au VIH." } }, { "@type": "Question", "name": "Comment les récepteurs CCR5 influencent-ils les complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent moduler la réponse immunitaire, augmentant le risque de complications." } }, { "@type": "Question", "name": "Quels sont les risques de résistance aux traitements ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une mauvaise adhésion au traitement peut entraîner une résistance virale et des complications." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment prévenir les complications liées au VIH ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un traitement antirétroviral efficace et un suivi médical régulier sont essentiels." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque du VIH ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les rapports sexuels non protégés, le partage de seringues et l'absence de dépistage." } }, { "@type": "Question", "name": "Le génotype de CCR5 influence-t-il le risque d'infection ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines variations génétiques peuvent conférer une protection contre le VIH." } }, { "@type": "Question", "name": "Comment l'usage de drogues affecte-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'usage de drogues injectables augmente le risque de transmission du VIH par le partage de seringues." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies immunitaires peuvent augmenter le risque." } }, { "@type": "Question", "name": "Quel rôle joue l'âge dans le risque d'infection ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les jeunes adultes sont souvent plus à risque en raison de comportements à risque plus fréquents." } } ] } ] }

Sources (10000 au total)

Endothelium-biomarkers for postthrombotic syndrome: a case-control study.

The postthrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT). Increase knowledge on the PTS pathophysiology and novel biomarkers are needed in order to predict PTS dev... A case-control study was conducted. Inclusion criteria were symptomatic and confirmed DVT patients treated with anticoagulants for at least 3 months. Villalta score was performed at the time of inclus... Thirty two patients and 61 controls were included. PTS patients showed higher levels of CEC (0.56/μl (0.34-1.5) vs. 0.20/μl (0.11-0.77); P = 0.04) and EPC (0.75/μl (0.38-1.52) vs. 0.09/μl (0.05-0.82);... The formation and early resolution of DVT are characterized by inflammation and endothelial/platelet activation. We have identified possible novel biomarkers such as CEC, EPC and fractalkine for the d...

Risk Factors for Postoperative Pneumonia: A Case-Control Study.

Postoperative pneumonia is a preventable complication associated with adverse outcomes, that greatly aggravates the medical expenses of patients. The goal of our study is to identify risk factors and ... A matched 1:1 case-control study, including adult patients who underwent surgery between January 2020 and June 2020, was conducted in the Second Affiliated Hospital of Kunming Medical University in Ch... Out of 17,190 surgical patients, 264 (1.54%) experienced postoperative pneumonia. Increased age, chronic obstructive pulmonary disease, emergency surgery, postoperative reduced albumin, prolonged vent... Postoperative pneumonia is associated with severe clinical outcomes. We identified six independent risk factors that can aid in risk stratification and management of patients at risk of postoperative ... www.chictr.org.cn, identifier: chiCTR2100045986....

Significance of temperature in antimuscarinic toxicity: a case-control study.

Antimuscarinic toxicity can result in temperature dysregulation, but the clinical significance of this is unclear. The objective of this study was to compare peak temperatures between antimuscarinic p... This was a case-control analysis at two large, urban, academic medical centers from January 1, 2016, through December 31, 2021. We compared peak temperature (... Fifty-six patients met inclusion criteria of which 23 developed severe outcomes: 16 seizures, 9 cases with hypotension, 5 intubations, and 2 ventricular dysrhythmias. Tmax amongst all patients ranged ... Maximum temperatures did not differ between patients with and without severe outcomes in the setting of antimuscarinic toxicity, and temperature was poorly predictive of outcomes. Our findings suggest...

A postmortem case control study of asbestos burden in lungs of malignant mesothelioma cases.

Asbestos lung content is regarded as the most reliable tool for causal attribution of malignant mesothelioma (MM) to previous asbestos exposures. However, there is a lack of studies on asbestos burden... Asbestos lung content has been assessed on formalin-fixed lung fragments using scanning electron microscopy coupled with energy dispersion spectroscopy (SEM-EDS) on individuals deceased from MM (cases... Asbestos and asbestos bodies (ABs) were found, respectively, in 73.7% and 43.2% of cases and in 28 and 22% of controls; in MM cases the most represented asbestos types were crocidolite and amosite, wh... The results suggest a correlation between asbestos burden in lungs and MM risk. The different concentration of chrysotile, as well as the different width of asbestos fibers in MM males and females mig...

Anemia and Idiopathic Intracranial Hypertension: A Case-Control Study.

Idiopathic intracranial hypertension (IIH) is a condition that mostly affects obese women of childbearing age but has been reported to be temporally related to new diagnoses of anemia. Despite these r... Consecutive IIH patients were recruited from neuro-ophthalmology clinics and matched by age and sex to consecutive patients attending neuro-ophthalmology clinics with diagnoses other than IIH. Complet... One hundred twenty-three IIH patients and 113 controls were included in the study. More IIH patients than controls had anemia (22.8%, 28/123 vs 10.6%, 12/113, P = 0.01) with an odds ratio of 2.48 (95%... Idiopathic intracranial hypertension patients have a higher prevalence of anemia compared with non-IIH neuro-ophthalmology patients. The anemia was mostly mild and may be explained by other factors re...

Study on the association between adverse drug reactions to opioids and gene polymorphisms: a case-case-control study.

Adverse drug reactions (ADRs) caused by opioid drugs show individual differences. Our objective was to explore the association between gene polymorphism and ADRs induced by opioid drugs.... Evidence-based medical data analysis was conducted for genes related to ADRs induced by opioid drugs to select target genes. Sixty patients with cancer pain who had ADRs after taking opioid drugs (mor... Based on a database search and evidence-based medical data, we identified CYP2D6*10, CYP3A5*3, ABCB1, and OPRM1 as target genes for detection. The results of statistical analysis showed no significant... Polymorphism of ABCB1 (062rs1045642) is related to ADRs caused by oxycodone, and the incidence of ADRs is higher with the allele T. Polymorphism of ABCB1 is expected to become a clinical predictor of ...

Systemic hormone therapy and dementia: A nested case-control and co-twin control study.

The effect of systemic hormone therapy (HT) on dementia risk is unclear. Our aim was to investigate the association between HT and dementia.... This register-based study consists of a nested case-control study and a co-twin control design, which controls for familial confounding, including shared genetics.... Through Danish national registries from 1995 to 2011, we identified: a) 2700 female singletons with incident dementia and 13,492 matched controls; b) 288 female twins with incident dementia and co-twi... The odds ratio (OR) for the association between systemic HT and dementia was 1.05, 95% CI = [0.93-1.19] in singletons and 2.10, 95% CI = [0.99-4.46] in twins. A statistically significant association w... Using Danish nationwide registries and controlling for education and for familial factors in a subsample, systemic HT was found to be associated with increased dementia risk if used before 2003, when ...